vs

Side-by-side financial comparison of DHT Holdings, Inc. (DHT) and GoodRx Holdings, Inc. (GDRX). Click either name above to swap in a different company.

GoodRx Holdings, Inc. is the larger business by last-quarter revenue ($194.8M vs $107.3M, roughly 1.8× DHT Holdings, Inc.). DHT Holdings, Inc. runs the higher net margin — 41.7% vs 2.8%, a 39.0% gap on every dollar of revenue. On growth, GoodRx Holdings, Inc. posted the faster year-over-year revenue change (-1.9% vs -24.5%).

DHT Holdings, Inc. is an independent international crude oil tanker operator that owns and manages a fleet of very large crude carriers. It offers marine transportation services for crude oil across major global trade routes, serving clients including leading oil producers, refineries, and commodity trading enterprises worldwide.

GoodRx Holdings, Inc. is an American healthcare company that operates a telemedicine platform and free-to-use website and mobile app that track prescription drug prices in the United States and provide drug coupons for discounts on medications. GoodRx compares prescription drug prices at more than 75,000 pharmacies in the United States. The platform allows users to consult a doctor online and obtain a prescription for certain types of medications.

DHT vs GDRX — Head-to-Head

Bigger by revenue
GDRX
GDRX
1.8× larger
GDRX
$194.8M
$107.3M
DHT
Growing faster (revenue YoY)
GDRX
GDRX
+22.5% gap
GDRX
-1.9%
-24.5%
DHT
Higher net margin
DHT
DHT
39.0% more per $
DHT
41.7%
2.8%
GDRX

Income Statement — Q3 FY2025 vs Q4 FY2025

Metric
DHT
DHT
GDRX
GDRX
Revenue
$107.3M
$194.8M
Net Profit
$44.8M
$5.4M
Gross Margin
Operating Margin
44.2%
11.6%
Net Margin
41.7%
2.8%
Revenue YoY
-24.5%
-1.9%
Net Profit YoY
27.3%
-19.5%
EPS (diluted)
$0.28
$0.02

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
DHT
DHT
GDRX
GDRX
Q4 25
$194.8M
Q3 25
$107.3M
$196.0M
Q2 25
$203.1M
Q1 25
$203.0M
Q4 24
$198.6M
Q3 24
$142.1M
$195.3M
Q2 24
$200.6M
Q1 24
$197.9M
Net Profit
DHT
DHT
GDRX
GDRX
Q4 25
$5.4M
Q3 25
$44.8M
$1.1M
Q2 25
$12.8M
Q1 25
$11.1M
Q4 24
$6.7M
Q3 24
$35.2M
$4.0M
Q2 24
$6.7M
Q1 24
$-1.0M
Operating Margin
DHT
DHT
GDRX
GDRX
Q4 25
11.6%
Q3 25
44.2%
7.5%
Q2 25
13.2%
Q1 25
11.5%
Q4 24
9.2%
Q3 24
29.7%
10.5%
Q2 24
9.9%
Q1 24
3.7%
Net Margin
DHT
DHT
GDRX
GDRX
Q4 25
2.8%
Q3 25
41.7%
0.6%
Q2 25
6.3%
Q1 25
5.4%
Q4 24
3.4%
Q3 24
24.8%
2.0%
Q2 24
3.3%
Q1 24
-0.5%
EPS (diluted)
DHT
DHT
GDRX
GDRX
Q4 25
$0.02
Q3 25
$0.28
$0.00
Q2 25
$0.04
Q1 25
$0.03
Q4 24
$0.01
Q3 24
$0.22
$0.01
Q2 24
$0.02
Q1 24
$0.00

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
DHT
DHT
GDRX
GDRX
Cash + ST InvestmentsLiquidity on hand
$81.3M
$261.8M
Total DebtLower is stronger
$495.0M
Stockholders' EquityBook value
$1.1B
$616.3M
Total Assets
$1.4B
$1.4B
Debt / EquityLower = less leverage
0.80×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
DHT
DHT
GDRX
GDRX
Q4 25
$261.8M
Q3 25
$81.3M
$273.5M
Q2 25
$281.3M
Q1 25
$301.0M
Q4 24
$448.3M
Q3 24
$73.8M
$423.8M
Q2 24
$524.9M
Q1 24
$533.3M
Total Debt
DHT
DHT
GDRX
GDRX
Q4 25
$495.0M
Q3 25
Q2 25
Q1 25
Q4 24
$500.0M
Q3 24
Q2 24
Q1 24
Stockholders' Equity
DHT
DHT
GDRX
GDRX
Q4 25
$616.3M
Q3 25
$1.1B
$600.7M
Q2 25
$643.0M
Q1 25
$654.3M
Q4 24
$724.7M
Q3 24
$1.0B
$696.4M
Q2 24
$669.4M
Q1 24
$631.1M
Total Assets
DHT
DHT
GDRX
GDRX
Q4 25
$1.4B
Q3 25
$1.4B
$1.3B
Q2 25
$1.3B
Q1 25
$1.3B
Q4 24
$1.4B
Q3 24
$1.5B
$1.4B
Q2 24
$1.5B
Q1 24
$1.5B
Debt / Equity
DHT
DHT
GDRX
GDRX
Q4 25
0.80×
Q3 25
Q2 25
Q1 25
Q4 24
0.69×
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
DHT
DHT
GDRX
GDRX
Operating Cash FlowLast quarter
$60.9M
$32.9M
Free Cash FlowOCF − Capex
$31.6M
FCF MarginFCF / Revenue
16.2%
Capex IntensityCapex / Revenue
0.6%
Cash ConversionOCF / Net Profit
1.36×
6.06×
TTM Free Cash FlowTrailing 4 quarters
$164.4M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
DHT
DHT
GDRX
GDRX
Q4 25
$32.9M
Q3 25
$60.9M
$76.0M
Q2 25
$49.6M
Q1 25
$9.4M
Q4 24
$44.7M
Q3 24
$80.1M
$86.9M
Q2 24
$9.7M
Q1 24
$42.6M
Free Cash Flow
DHT
DHT
GDRX
GDRX
Q4 25
$31.6M
Q3 25
$74.3M
Q2 25
$49.2M
Q1 25
$9.3M
Q4 24
$44.6M
Q3 24
$86.5M
Q2 24
$9.4M
Q1 24
$42.2M
FCF Margin
DHT
DHT
GDRX
GDRX
Q4 25
16.2%
Q3 25
37.9%
Q2 25
24.2%
Q1 25
4.6%
Q4 24
22.4%
Q3 24
44.3%
Q2 24
4.7%
Q1 24
21.3%
Capex Intensity
DHT
DHT
GDRX
GDRX
Q4 25
0.6%
Q3 25
0.9%
Q2 25
0.2%
Q1 25
0.1%
Q4 24
0.1%
Q3 24
0.2%
Q2 24
0.1%
Q1 24
0.2%
Cash Conversion
DHT
DHT
GDRX
GDRX
Q4 25
6.06×
Q3 25
1.36×
67.94×
Q2 25
3.86×
Q1 25
0.85×
Q4 24
6.64×
Q3 24
2.28×
21.91×
Q2 24
1.45×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

DHT
DHT

Segment breakdown not available.

GDRX
GDRX

Prescription Transactions Revenue$124.7M64%
Other$44.4M23%
Subscription Revenue$21.6M11%
Other Revenue$4.1M2%

Related Comparisons